Frazier Life Sciences Management’s Trevi Therapeutics TRVI Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$119M	Sell	9,939,547 -319,862	-3%	-$3.58M	3.05%	10
2025 Q4	$128M	Hold	10,259,409	–	–	3.45%	8
2025 Q3	$93.9M	Hold	10,259,409	–	–	2.81%	11
2025 Q2	$56.1M	Hold	10,259,409	–	–	2.24%	11
2025 Q1	$64.5M	Sell	10,259,409 -405,365	-4%	-$1.93M	2.95%	9
2024 Q4	$43.9M	Buy	10,664,774 +3,283,684	+44%	+$10.5M	1.82%	14
2024 Q3	$24.7M	Hold	7,381,090	–	–	0.99%	25
2024 Q2	$22M	Hold	7,381,090	–	–	1.03%	26
2024 Q1	$25.5M	Hold	7,381,090	–	–	1.07%	27
2023 Q4	$9.89M	Buy	7,381,090 +500,000	+7%	+$757K	0.53%	42
2023 Q3	$15M	Hold	6,881,090	–	–	1%	24
2023 Q2	$16.4M	Buy	6,881,090 +217,500	+3%	+$548K	0.98%	28
2023 Q1	$12.3M	Hold	6,663,590	–	–	0.89%	26
2022 Q4	$12.9M	Buy	6,663,590 +1,260,000	+23%	+$2.48M	0.8%	25
2022 Q3	$8.32M	Buy	5,403,590 +4,231,963	+361%	+$13.9M	0.64%	33
2022 Q2	$3.29M	Buy	+1,171,627	New	+$2.88M	0.31%	33